Changing Agendas on Sleep, Treatment and Learning in Epilepsy

Rolandic Epilepsy Clinical Trial

— CASTLE  

Official title:

Randomised Factorial Design Controlled Trial Comparing Carbamazepine, Levetiracetam or Active Monitoring Combined With or Without Sleep Behaviour Intervention in Treatment Naive Children With Rolandic Epilepsy

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04610879
• Other study ID #: CASTLE
• Secondary ID: 2018-003893-29RP
• Status: Terminated
• Phase: Phase 4
• Start date: August 2, 2019
• Est. completion date: September 23, 2020

Study information

• Verified date: October 2020
• Source: King's College London
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Rolandic epilepsy (RE) is the most common type of epilepsy. Children with RE have seizures and can often find that their learning, sleep, behaviour, self-esteem and mood are affected. As part of standard NHS care, children diagnosed with RE may be treated with standard anti-epileptic medicines, like carbamazepine, or no medicine at all. The medicines used to treat epilepsy often slow down a child's thinking and learning. In the past, doctors believed this was an acceptable price to pay to reduce seizures. However, with RE, where the seizures usually stop in teenage years, investigators do not know if it is better to treat these children with medicines or not, especially if the medicines might have a negative effect on their learning. A newer medicine called levetiracetam has also been found to work in children with RE and has shown less problems with thinking and learning in adults. However, it is still no known if this is also the case for children and it has not been proven which of the three options (carbamazepine, levetiracetam or no treatment) would be best for RE patients. The CASTLE study aims to find this out. In addition, it has been found that seizures often happen when a child has had poor sleep and they often come at night or early in the morning. It has been shown that sleep can be improved through practice without the need of medicines. There are established guidelines to help toddlers go to sleep, but nothing available that helps young people with epilepsy and their parents improve their sleep quality. In the CASTLE study, a sleep training plan has been developed for children with epilepsy and the trial aims to find out whether following this sleep training plan results in less seizures than using no sleep training at all.

Description:

The trial is a phase IV randomised factorial design controlled trial comparing carbamazepine, levetiracetam or active monitoring combined with or without sleep behaviour intervention. A factorial trial design has been used as this approach enables the efficient simultaneous investigation of AED (carbamazepine; levetiracetam; no AED) and sleep behaviour intervention (vs standard care) by including all participants in both analyses. In a factorial trial it is also possible to consider both the separate effects of each intervention and the benefits of receiving both interventions together (for example levetiracetam and sleep intervention). The CASTLE trial will take place in NHS out-patient paediatric epilepsy and general paediatric clinics in the United Kingdom (UK). Once consent has been obtained from the appropriate adult, and assent from the child if appropriate, by the delegated member of the research team the eligibility assessments will be completed, full eligibility confirmed (confirmation must be by a medically qualified doctor) and baseline data will be collected prior to randomisation. Randomisation will be performed via a web based tool accessed by research team at site. This system is generated centrally by the Clinical Trial Research Centre (CTRC) using a computer algorithm concealed from the investigators and research teams/trial management group. In order to balance the groups, minimisation for variables believed to influence disease outcome and end points will be built into the randomisation algorithm. Participants will be randomised to treatment with carbamazepine, levetiracetam or active monitoring. Where randomised to drug treatment, the randomised treatment should ideally begin on the day of randomisation or within 14 days of randomisation at the latest. Randomised treatment will continue for a minimum of 12 months and a maximum of 48 months. All treatments will be procured, prescribed and issued as per routine NHS practice. Clinical data capture will be in the form of paper copies of Case Report Forms (CRFs) that will be returned as an on-going process from each centre to the CTRC. Patient/parent reported data will be collected directly on paper at each outpatient visit with the exception of CANTAB, which will be collected on iPads at the centre. All trial documents (except raw Hospital Episode Statistics (HES) from NHS digital that will only be retained for 1 year) will be retained for 25 years from the End of Trial. The PI at each investigational centre must make arrangements to store the essential trial documents, (as defined in Essential Documents for the Conduct of a Clinical Trial (ICH E6, Guideline for Good Clinical Practice)) including the ISF, until the CTRC informs the investigator that the documents are no longer to be retained

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: September 23, 2020
• Est. primary completion date: September 23, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 5 Years to 12 Years

Eligibility

Inclusion Criteria:

1. Children diagnosed with RE (see International League Against Epilepsy Diagnostic Manual at https://www.epilepsydiagnosis.org/syndrome/ects-overview.html)

2. EEG showing focal sharp waves with normal background (see International League Against Epilepsy Diagnostic Manual at https://www.epilepsydiagnosis.org/syndrome/ects-eeg.html)

3. Aged =5 years and <13 years at the time of randomisation

4. Currently untreated with antiepileptic drugs

5. Written informed consent received from person with parental responsibility/legal representative.

6. Family have an email address and regular internet access (for online sleep intervention)

7. Parent and child are to have a good understanding of the English language

Exclusion Criteria:

1. Known contraindication to any of the trial drugs

2. Previously treated for epilepsy with antiepileptic drugs

Related Conditions & MeSH terms

• Epilepsy
• Epilepsy, Rolandic
• Rolandic Epilepsy

Intervention

Drug:
• Carbamazepine
Treatment will be procured, prescribed and issued as per routine NHS practice. Generics can be prescribed.
• Levetiracetam
Treatment will be procured, prescribed and issued as per routine NHS practice. Generics can be prescribed.

Behavioral:
• Parent based sleep (PBS) intervention
The PBS intervention is an e-learning package for parents/primary carers and children with epilepsy. The PBS intervention offers parents education about normal sleep, advice about sleep-promoting practices and targeted strategies parents can employ to help their children to ''learn'' an appropriate set of sleep behaviours/habits and/or to unlearn inappropriate sleep behaviours.

Locations

Country	Name	City	State
United Kingdom	King's College Hospital NHS Foundation Trust	London
United Kingdom	Tameside Hospital	Manchester
United Kingdom	Whiston Hospital	Whiston

Sponsors (6)

Lead Sponsor	Collaborator
King's College London	Bangor University, Edge Hill University, King's College Hospital NHS Trust, Oxford Brookes University, University of Liverpool

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Summary of actigraphy variables (total sleep time/sleep latency/sleep efficiency) averaged over a 1-week period	To determine which sleep parameters change in primary carer and child dyads in different treatment groups	1 week actigraphy (arranged centrally via Oxford unit) at baseline, 3 and 12 months
Primary	Time to 6-month seizure remission	To determine if carbamazepine or levetiracetam are superior to no anti-epileptic drugs	Up to 48 months
Primary	Change from baseline to total sleep problem score as measured by the Children's Sleep Habits Questionnaire (CSHQ)	To determine if a Parent-Based Sleep intervention is superior to standard care	At 3 months
Secondary	Total costs measured in Quality-Adjusted Life Years (QALYs)	To estimate the cost-utility of carbamazepine, levetiracetam and PBS	At 0, 3, 12, 24, 36 and 48 months
Secondary	Time taken from randomisation to decision by child, parent or treating physician to be withdrawn from treatment due to inadequate seizure control or unacceptable adverse reactions	To compare time to treatment failure due to inadequate seizure control or unacceptable adverse reactions	At 3, 6,12, 24, 36 and 48 months
Secondary	Time taken from randomisation to decision by child, parent or treating physician to be withdrawn from treatment due to inadequate seizure control	To compare time to treatment failure due to inadequate seizure control	At 3, 6,12, 24, 36 and 48 months
Secondary	Time taken from recruitment to decision by child, parent or treating physician to be withdrawn from trial due to unacceptable adverse reactions	To compare time to treatment failure due to unacceptable adverse reactions	At 3, 6,12, 24, 36 and 48 months
Secondary	Time to first seizure based on seizure report	To compare time to first seizure	At 3, 6,12, 24, 36 and 48 months
Secondary	Time to 12-month seizure remission based on seizure report	To compare time to 12-month remission from seizures	At 3, 6,12, 24, 36 and 48 months
Secondary	Total sleep problem score as measured by the Children's Sleep Habits Questionnaire (CSHQ)	To determine if a Parent-Based Sleep intervention is superior to standard care	At 12, 24, 36 and 48 months
Secondary	Total score in three chosen assessments delivered by the Cambridge Neuropsychological Test Automated Battery (CANTAB)	To compare measures of cognition across the different treatment groups	At 0, 3, 6,12, 24, 36 and 48 months
Secondary	Score change in Health Related Quality of Life in Children with Epilepsy - Child self-report scale (CHEQOL)	To compare Health Related Quality of Life across the different treatment groups	At 0, 12, 24, 36 and 48 months
Secondary	Total score on Strengths and Difficulties Questionnaire (SDQ)	To compare measures of children's behaviour across the different treatment groups	At 0, 12, 24, 36 and 48 months
Secondary	Records of adverse reactions	To identify any adverse reactions and their rate	At 3, 6, 12, 24, 36 and 48 months
Secondary	Score changes in Child Health Utility instrument (CHU9D)	To estimate child health utilities and Quality-Adjusted Life Years (QALYs) across the different treatment groups	At 0, 3, 12, 24, 36 and 48 months
Secondary	Score changes in EQ-5D-Y	To estimate child health utilities and Quality-Adjusted Life Years (QALYs) across the different treatment groups	At 0, 3, 12, 24, 36 and 48 months
Secondary	EQ-5D-5L score change	To estimate health utilities and Quality-Adjusted Life Years (QALYs) across parents in the different treatment groups	At 0, 3, 12, 24, 36 and 48 months
Secondary	Score changes in Parental Self-Efficacy Measure (PSAM)	To compare parenting self-efficacy across the different treatment groups	At 0, 3, 12, 24, 36 and 48 months
Secondary	Total sickness related school absences (days)	To compare sickness related school absences across the different treatment groups	At 0, 3, 6, 12, 24, 36 and 48 months
Secondary	Resource Use Questionnaire	To determine the costs to the National Health Service (NHS)	At 3, 12, 24, 36 and 48 months
Secondary	Hospital Episode Statistics (HES) Data	To determine the costs to the National Health Service (NHS)	48 months, measured for the participant's study duration
Secondary	Patient Level Information and Costing System (PLICS) Data	To determine the costs to the National Health Service (NHS)	48 months, measured for the participant's study duration